(Q34098328)

31 July 2017

title

Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study (English)

1 reference

31 July 2017

0 references

4

Barry Storer

1 reference

31 July 2017

7

H Joachim Deeg

1 reference

31 July 2017

1

Bart L Scott

1 reference

31 July 2017

5

Pamela Becker

1 reference

31 July 2017

2

Aravind Ramakrishnan

1 reference

31 July 2017

6

Steve Petersdorf

1 reference

31 July 2017

Mark Fosdal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

16 March 2010

1 reference

British Journal of Haematology

31 July 2017

published in

1 reference

31 July 2017

volume

149

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

706-710

1 reference

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

The World Health Organization (WHO) classification of the myeloid neoplasms

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931581

Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome

28 October 2018

1 reference

12 December 2020

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

12 December 2020

A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome

1 reference

12 December 2020

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

1 reference

12 December 2020

Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome

1 reference

12 December 2020

Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression

1 reference

12 December 2020

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia

1 reference

12 December 2020

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

12 December 2020

Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin

1 reference

12 December 2020

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

1 reference

12 December 2020

Antithymocyte globulin for patients with myelodysplastic syndrome

1 reference

12 December 2020

Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles

1 reference

12 December 2020

A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome

1 reference

12 December 2020

Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study

1 reference

12 December 2020

10.1111/J.1365-2141.2010.08145.X

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference